Blood Transfusion Diagnostics Market Size, Share & Trends Analysis Report By Product Type (Instruments, Consumables), By Technology (Serology, Nucleic Acid Tests, Microarray & Next-generation Sequencing, Others), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Blood Transfusion Diagnostics Market Size

The global blood transfusion diagnostics market size was valued at USD 6.1 billion in 2025 and is projected to grow from USD 6.55 billion in 2026 to USD 11.57 billion by 2034, registering a CAGR of 7.37% during the forecast period from 2026 to 2034. North America dominated the blood transfusion diagnostics market with a market share of 38.97% in 2025.

The blood transfusion diagnostics market expansion is driven by rising surgical volumes, oncology therapies, trauma cases, and increasing prevalence of hematological disorders such as thalassemia and sickle cell disease. According to the World Health Organization, over 118 million blood donations are collected each year, reinforcing the need for advanced screening technologies to ensure transfusion safety. A key market driver is the shift toward nucleic acid testing (NAT) and pathogen reduction systems, which reduce window-period infections, including HIV, HBV, and HCV. Digital blood bank automation and RFID-based cold chain tracking are improving traceability and inventory optimization. Aging population and rising elective surgeries increase demand for compatibility testing.

Blood Transfusion Diagnostics Segmentation Analysis

By Product Type

The instruments segment is expected to grow at a CAGR of 8.14% during the forecast period due to increasing deployment of high-throughput serology platforms that support rapid sample processing in centralized blood banks handling large donor volumes. Rising demand for compact, cartridge-based analyzers in emergency and point-of-care transfusion settings is also accelerating adoption. Expansion of fully automated sample handling systems is improving workflow efficiency and supporting segment growth.

The consumables segment is expected to grow at a CAGR of 8.73% during the forecast period, driven by rising demand for single-use blood collection tubes with specialized anticoagulants like EDTA, citrate, and gel separators. Increasing use of high-sensitivity reagent kits for irregular antibody detection and infectious disease screening is also driving recurring procurement. Rising use of leukoreduction filters, cross-match cards, and disposable microcolumns supports standardized workflows.

Request Customizationto receive a tailored report.

By Technology

Serology accounted for the largest share of 44.70% in 2025 due to widespread reliance on gel card and tube agglutination methods for routine blood grouping in decentralized hospital labs. High use in emergency compatibility screening for trauma and obstetric hemorrhage cases supports demand. Additionally, cost-effective reagent-based workflows make serology preferred over molecular methods in routine transfusion workflows.

The nucleic acid tests segment is expected to have the fastest growth, registering a CAGR of 8.94% during the forecast period. This growth is driven by its ability to detect low-level viral DNA/RNA during the window period of infections like HIV, HBV, and HCV, improving transfusion safety. Increasing adoption in centralized blood screening labs ensures high-throughput donor testing with pooled sample strategies. Regulatory mandates are shifting screening to NAT-inclusive workflows, increasing demand for molecular blood testing platforms.

By End User

Hospitals led the end-user segment with a share of 44.65% in 2025 due to high perioperative transfusion workflows in trauma, oncology, and transplant units requiring continuous compatibility testing. Integrated hospital blood banks ensure rapid emergency blood release. Additionally, in-house immunohematology labs support 24/7 critical care transfusion decisions, reducing dependence on external centers.

The blood banks segment is expected to grow at a CAGR of 9.36% during the forecast period, fueled by rising centralization of donor collection, processing, and storage under national blood safety programs that consolidate testing in dedicated facilities. Increasing demand for component-level separation such as plasma, platelets, and packed red cells supports higher diagnostic testing volumes.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America: Market Leadership through High Adoption of Automated Immunohematology Analyzers and Strong Adoption of Laboratory Automation in Hospitals

The North America blood transfusion diagnostics market accounted for the largest regional share of 38.97% in 2025, supported by high adoption of automated immunohematology analyzers in large hospital networks and trauma centers, especially in the US Level I trauma system. Strong integration of hospital blood banks with electronic health records under interoperability mandates also boosts efficiency. Advanced rare donor registries like the American Rare Donor Program support complex transfusion cases, improving compatibility for multi-transfused patients and strengthening demand for molecular blood typing solutions.

The blood transfusion diagnostics market in the US is growing due to highly structured hospital-based blood management programs in large integrated health systems such as Mayo Clinic and Cleveland Clinic, where standardized transfusion protocols drive frequent use of advanced compatibility testing. The presence of the FDA’s stringent biologics regulation framework also accelerates adoption of serological and molecular assays to meet compliance requirements. The US military’s centralized blood program for battlefield and trauma preparedness increases demand for portable diagnostic platforms in emergency and deployment settings.

The blood transfusion diagnostics market expansion in Canada is supported by centralized blood systems operated by Canadian Blood Services and Héma-Québec, enabling standardized testing and advanced immunohematology adoption. High prevalence of chronic transfusion-dependent disorders like sickle cell disease in immigrant populations increases demand for extended antigen matching. Strong adoption of hospital-wide laboratory automation in urban tertiary centers supports rapid emergency transfusion workflows across geographically dispersed healthcare facilities.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growth Driven by Growing Blood Safety Programs and Highly Centralized Transfusion Services

The Asia Pacific blood transfusion diagnostics market is expected to register the fastest regional growth with a CAGR of 9.87%. This growth is driven by the expansion of national blood safety programs in countries like India, China, and Australia, which are strengthening mandatory infectious disease screening and compatibility testing standards. Rising surgical tourism in India and Thailand is increasing demand for rapid pre-transfusion testing. Growing investment in domestic in vitro diagnostics manufacturing in China and India is improving the affordability and accessibility of automated immunohematology analyzers across secondary and tertiary care hospitals.

China’s blood transfusion diagnostics market is expanding due to the rapid modernization of provincial blood centers under the National Health Commission’s centralized blood safety network, which enforces standardized serology and nucleic acid testing nationwide. Large-scale hospital digitization under Smart Hospital initiatives is integrating blood bank systems with HIS platforms for real-time cross-matching. Rising demand from high-volume surgical oncology centers in tier-1 cities, along with domestic production of automated immunohematology analyzers by local IVD manufacturers, is improving affordability and accelerating adoption.

The blood transfusion diagnostics market growth in Singapore is supported by highly centralized transfusion services under the Health Sciences Authority and Singapore Red Cross, ensuring strict national-level blood screening and compatibility protocols. Advanced adoption of fully automated immunohematology platforms in tertiary hospitals like SGH and NUH enhances precision testing and turnaround speed. Singapore’s role as a regional medical hub for complex surgeries and oncology care increases demand for high-accuracy cross-matching and rare blood compatibility testing in multinational patient inflows.

Competitive Landscape

The blood transfusion diagnostics market landscape is moderately consolidated, with a few global players dominating due to strong immunohematology portfolios, automated analyzers, and molecular testing platforms. Companies such as Roche, bioMérieux, Grifols, and Abbott lead the market by offering integrated solutions covering blood grouping, antibody screening, and compatibility testing. Their advantage comes from continuous R&D in automation, digital blood bank integration, and regulatory compliance across major regions. Mid-sized players focus on niche areas like rare donor matching and reagent development, while new entrants face high barriers due to strict validation, quality standards, and hospital integration requirements.

List of Key and Emerging Players in Blood Transfusion Diagnostics Market